Helicobacter pylori is associated with chronic gastritis and peptic ulcer disease (6, 16) . Numerous clinical studies indicate that eradication of H. pylori by treatment with bismuth or bismuth-antibiotic combinations leads to an improvement of gastritis and drastically decreases the rate of relapse of peptic ulcers (14, 15, 22, 23) .
Treatment with antibiotic combinations, including proton pump inhibitors such as omeprazole (2) , is generally recommended both to increase activity and to reduce the risk of the organism developing resistance (27) . Therapy may need to be guided by antimicrobial sensitivity testing of cultured organisms.
H. pylori is susceptible to a wide range of antimicrobial agents in vitro (7, 8, 12, 19, 26) . In vivo, however, some of these antibiotics, including erythromycin, ofloxacin, and ciprofloxacin, have suboptimal activities (10, 17, 28) . The lack of in vivo efficacy may be related to the instability of these antimicrobial agents in the acidic gastric environment, although this point has not been conclusively demonstrated (18) . Fluoroquinolone antimicrobial agents are widely used for oral treatment of respiratory, gastrointestinal, and urinary tract infections. These antibacterial agents showed in vitro activity against H. pylori (25), although they were not effective in eradicating infections (10, 24) .
In an ongoing research program concerning structure-activity studies of quinolone antibacterial agents, we recently identified a new class of potent antibacterial quinolones in which the fundamental C-6 fluorine atom was replaced by an amino group (3, 4) . In the present study, some representative 6-aminoquinolones were evaluated in vitro against H. pylori strains. In addition, selected 6-nitro and 6-fluoro counterparts were also assayed for comparative purposes. The compounds investigated in this study are shown in Fig. 1 .
The denominations of the compounds investigated are as follows:
All of these compounds were provided by Mediolanum Farmaceutici S.p.A. (Milan, Italy). Ciprofloxacin (Sigma Aldrich S.r.l., Milan, Italy), clarithromycin (Abbott S.p.A., Campoverde di Aprilia, Italy), and metronidazole (Sigma Aldrich) were used as control drugs.
Thirty-two H. pylori strains were isolated from biopsy material from patients undergoing endoscopy at the University Hospital of Messina, Messina, Italy. Fresh isolates were stored in liquid nitrogen until they were subcultured for this study. All strains were seeded on Columbia agar (Oxoid) supplemented with 7% defibrinated horse blood and grown for 3 days under microaerophilic conditions. Bacterial growth was taken from the plates and resuspended in sterile saline. The inoculum was prepared to contain about 5 ϫ 10 7 CFU/ml by adjusting the turbidity of the suspension to match the MacFarland no. 1 standard. Ten-microliter aliquots of these suspensions were inoculated on Columbia blood agar plates containing serial twofold dilutions of the drugs tested (20) . All plates, including control plates, were incubated for 72 h in a microaerophilic atmosphere. The MIC was considered the lowest concentration of an antimicrobial agent causing total inhibition of bacterial growth. The susceptibilities of the strains were expressed as the MICs at which 50 and 90% of the isolates were inhibited (MIC 50 and MIC 90 , respectively). The MIC 50 s and MIC 90 s of the 14 antibiotics tested are summarized in Table 1 . The bacterial isolates were only moderately sensitive to metronidazole, which had an MIC 50 and an MIC 90 of 3.125 and 12.5 g/ml, respectively. For 10 of 32 (31%) of the H. pylori strains, met-ronidazole MICs were Ͼ6.25 g/ml (data not shown), and these strains were therefore considered resistant to that drug (1, 11) . This prevalence of resistance to metronidazole is similar to that reported elsewhere (5, 9, 13, 21). The 6-nitroquinolone derivatives VG 6/1, MF 5168, and ML 4/11e (compounds 1a, 2a, and 4a, respectively, in Fig. 1) had the highest activities, with MIC 90 s of either 1.25 or 2.5 g/ml ( Table 1 ). The 6-aminoquinolones MF 5112 and MF 5143 (compounds 2bЈ and 4b respectively, in Fig. 1 ) had MIC 50 s of 0.156 and 0.078 g/ml and MIC 90 s of 1.25 and 5 g/ml, respectively. VG 6/1 and MF 5168 had lower MIC 90 s but higher MIC 50 s than clarithromycin, one of the most active compounds to date against H. pylori. This reflected the separation of H. pylori strains into two distinct populations with respect to clarithromycin resistance. In fact, 10 of the 32 strains examined had clarithromycin MICs of Ͼ1.25 g/ml and were therefore considered resistant to that drug. Of these 10 resistant strains, 8 had VG 6/1 MICs of Յ0.625 g/ml, 8 had MF 5168 MICs of Յ0.312 g/ml, and 7 had ML 4/11e MICs of Յ0.312 g/ml. When comparing three sets of compounds differing only in the C-6 substituent (VG 6/1, MF 5137, and MF 9053; MF 5168, MF 5101, and MF 9056; or ML 4/11e and MF 5143), the order of effectiveness of derivatives was always 6-nitro Ͼ 6-amino Ͼ 6-fluoro (Table 1 and Fig. 1 ). The MIC of ciprofloxacin was Ͼ5 g/ml for 3 of 32 strains examined. Table 2 shows the MICs of desfluoroquinolones against these three ciprofloxacin-resistant strains. The data suggest that there is a lack of cross-resistance between ciprofloxacin and the new desfluoroquinolones. Table 3 shows the activities of selected compounds at different pH values. Lowering the pH resulted in an eightfold increase in the MIC 50 s of both ciprofloxacin and clarithromycin. MF 5143 had the same MIC 50 s and MIC 90 s at pH 5.5 and pH 7.2, indicating a high degree of stability in an acidic environment. The MIC 50 s of MF 9053 and VG 6/1, increased only two-and fourfold, respectively, at a pH of 5.5 relative to the values obtained at a neutral pH. The MIC range of the aminoquinolone MF 5137 was affected by pH changes, with the lowest MICs rising significantly between pH 7.2 and pH 5.5. Specifically, six strains with MICs of 0.009 g/ml at pH 7.2 had MICs of 0.078 g/ml at pH 5.5. However, these variations did not result in an increased prevalence of resistant strains at pH 5.5, and the MIC 50 of this compound remained essentially unchanged.
Although these data indicated that the new quinolones tested had satisfactory stability at an acidic pH, it is difficult to draw firm conclusions regarding the relationship between C-6 substitutions and variations in antibacterial activities at different pHs. C-6 substitutions apparently did not affect antibacterial activities at pH 5.5, since the fluoroquinolone MF 9053 was as stable to low pH as the corresponding amino (MF 5137) and nitro (VG 6/1) compounds. The clinical isolates used here showed a broad range of ciprofloxacin resistance, likely due to the accrual of a number of different mutations affecting permeability and targets. Studies using well-characterized strains with selected permeability-related mutations should better clarify the relationships between C-6 substitutions, the ionization state of quinolones, and resistance mechanisms related to permeability.
In conclusion, data presented here indicate that new quinolone compounds which bear an amino or nitro group at the C-6 position are active in vitro against H. pylori even at a low pH. Further in vivo studies, however, are needed to determine if this new class of compounds can be used to eradicate H. pylori infections.
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